Vaccitech Overview
- Founded
-
2016
- Status
-
Public
- Employees
-
72
- Stock Symbol
-
VACC
- Investments
-
1
- Share Price
-
$5.40
- (As of Thursday Closing)
Vaccitech General Information
Description
Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- The Schrodinger Building, Heatley Road
- The Oxford Science Park
- Oxford OX4 4GE
- England, United Kingdom
+44 01865 000000
Vaccitech Timeline
Vaccitech Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.40 | $6.21 | $2.97 - $17.99 | $201M | 37.2M | 18.4K | -$1.08 |
Vaccitech Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (13,002) | 162,293 | ||
| Revenue | 15,072 | 268 | 4,821 | 6,845 |
| EBITDA | (32,493) | (47,872) | (14,030) | |
| Net Income | (33,001) | (50,865) | (17,706) | |
| Total Assets | 286,123 | 280,715 | 50,666 | 19,043 |
| Total Debt | 6,735 | 7,222 | 46,364 | 1,778 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Vaccitech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vaccitech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Vaccitech Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunother
Drug Discovery
Oxford, United Kingdom
72
As of 2021
00000
0000
0000-00-00
00000000
00000
000000
inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000000000000
Plymouth Meeting, PA
000
As of 0000
000.00
00000000
000.00
000000
boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000000000000
Gaithersburg, MD
00
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
Vaccitech Competitors (63)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 00000000 | Venture Capital-Backed | San Carlos, CA | 00 | 00000 | 000000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 0 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
Vaccitech Patents
Vaccitech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11191825-B2 | Compositions and methods for vaccination against influenza | Active | 16-Sep-2016 | 0000000000 | 0 |
| US-20190307877-A1 | Compositions and methods for vaccination against influenza | Granted | 16-Sep-2016 | 000000000 |
Vaccitech Executive Team (8)
Vaccitech Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Hammacher | Oxford Science Enterprises | Board Member | 000 0000 |
| Anne Phillips MD | Vaccitech | Board Member | 000 0000 |
| Joseph Scheeren | Vaccitech | Board Member | 000 0000 |
| Karen Dawes | Vaccitech | Board Member | 000 0000 |
| Pierre Morgon | Self | Board Member | 000 0000 |
Vaccitech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Vaccitech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vaccitech Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 10-Dec-2021 | 0000000000 | Biotechnology | 0000000 0 |
Vaccitech Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 000000 00000000000 | Biotechnology | Baltimore, MD | 0000 |